Introduction
============

Premature ventricular complexes (PVCs) are very common, appearing most frequently in patients with hypertension, obesity, sleep apnea, and structural heart disease \[[@b1-krcp-36-167]\]. In general, PVCs in the structurally normal heart are considered benign \[[@b2-krcp-36-167]\], though they have been associated with a more than two-fold higher risk of cardiovascular complications, including stroke \[[@b3-krcp-36-167]\] and death \[[@b4-krcp-36-167]\]. PVCs have progressively more been recognized as a primary cause for deteriorating left ventricular (LV) systolic function, and heart failure in some subjects, once apparent causes such as cardiac ischemia, valvular disease, toxic metabolic or infiltrative diseases, and persistent tachycardia has been excluded. The pathogenesis of PVC-mediated cardiomyopathy is uncertain \[[@b5-krcp-36-167],[@b6-krcp-36-167]\]. The range of benign outflow tract PVCs sorts from single PVCs to repetitive non-sustained ventricular tachycardia to paroxysmal sustained ventricular tachycardia \[[@b7-krcp-36-167]\]. In rare circumstances, short-coupled right ventricular outflow tract PVCs can initiate polymorphic ventricular tachycardia \[[@b8-krcp-36-167]\], while even shorter-coupled PVCs frequently originating from the fascicular system or papillary muscles can trigger ventricular fibrillation \[[@b9-krcp-36-167],[@b10-krcp-36-167]\]. However, the best progression of action to pursue PVCs that are polymorphic and refractory to medical management is not clear. Possible treatment options embrace mapping and ablating them one by one or attempting a new, alternative therapy.

Sympathetic hyperactivity plays a key title role in the development, maintenance, and aggravation of ventricular arrhythmias \[[@b11-krcp-36-167]\]. Recently, Professor Esler's group suggested that endurance training influences many factors which may mediate a reduction in sympathetic activity \[[@b12-krcp-36-167]\]. Endurance exercise training obviously lowers sympathetic activity in sympatho-excitatory disease states \[[@b13-krcp-36-167],[@b14-krcp-36-167]\] and is well-tolerated by patients with chronic kidney disease (CKD) \[[@b15-krcp-36-167],[@b16-krcp-36-167]\]. The outcome of endurance training on renal sympathetic nerve activity has been measured in healthy humans \[[@b17-krcp-36-167]\], but not in humans with CKD. Thus, proofs of principle studies are required.

Methods
=======

In this study, we conducted a prospective, longitudinal study in 40 CKD, controlled hypertensive and sedentary patients with polymorphic PVCs. At baseline, all of them started to use β blocker (bisoprolol 10 mg). However 20 patients remained sedentary, serving as a control group, and the other 20 subjects began to practice physical activity (starting with 150 minutes of moderate activity per week, as recommended by the Brazilian Ministry of Health, and increasing progressively until 300 minutes of moderate to intensive exercise per week). The study was piloted in accordance with the Helsinki Declaration and approved by the Ethics Committee of Hospital e Clínica São Gonçalo (HCSG2013-004). All patients signed the written informed consent before inclusion. In the present study, we aim to evaluate the effects of the exercise in the changes of the numbers of PVCs and heart rate (HR) by 24-hour-Holter, modifications in estimated glomerular filtration rate (eGFR) and the albumin:creatinine ratio (ACR) in all patients.

Definition of polymorphic PVCs
------------------------------

Polymorphic PVCs were defined as 3 or more PVCs of different morphologies in a high incidence each one.

Study subjects
--------------

This study was conducted in the state of Rio de Janeiro, Brazil in the Hospital e Clínica São Gonçalo. Patients were recruited from January 2014 to December 2015 and were derived from Arrhythmias and Artificial Cardiac Pacing Service of the same hospital. Patients who had the combination of the following criteria were consecutively enrolled: 1) mean 24-hour systolic ambulatory blood pressure measurements (ABPM) \< 130/\< 80 mmHg; 2) age between 18 and 70 years; 3) structurally normal heart to myocardial scintigraphy and transthoracic echocar-diography, without ischemia, fibrosis area or any other illness, with a LV ejection fraction of \> 50% as measured by echocardiography (Simpson's method); 4) presenting \> 25,000 polymorphic PVCs in 24-hour-Holter monitoring at baseline; 5) experience symptoms such as dyspnea, palpitation, dizziness, pre-syncope or syncope; 6) not having undergone previous treatment; 7) glomerular filtration rate estimated by the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation, eGFR \[[@b18-krcp-36-167]\] \< 60 mL/min/1.73 m^2^; and 8) be able to read, understand and sign the informed consent form.

Patients with any of the following criteria were excluded: 1) pregnancy; 2) valvular disease with significant hemodynamic repercussions; 3) myocardial infarction, unstable angina, stroke or transient ischemic attack within the previous 6 months; 4) mobility deficit; 5) psychiatric disease; 6) patients unable to be followed clinically; 7) patient known to have drug addiction or alcohol, can affect the ability to understand or follow medical instructions; 8) patient has a serious disease, which in the opinion of the investigator, may adversely affect the safety and/or efficacy of the participant or the study.

24-hour-Holter monitoring
-------------------------

Patients underwent a 24-hour-Holter monitoring (Galix Biomedical Instrumentation, Miami, FL, USA). A 3-channel recorder was used to record the electrocardiographic traces, calculate the mean HR, the quantity and the morphologies of PVCs at baseline, 3, 6, 9 and 12 months after β blocker only or β blocker + exercise onset.

24-hour ABPM
------------

ABPM was performed for 24 hours at baseline with a clinically validated device (CardioMapa; Cardios, São Paulo, Brazil). The device was set to measure every 15 minutes during the day (06:00 to 22:00) and every 30 minutes during sleep (22:00 to 06:00). Patients were instructed to continue their regular activities during the recording and go to bed no later than 23:00. The waking period typically included 08:00 to 22:00 and the sleep period 24:00 to 06:00 \[[@b19-krcp-36-167]\]. All individuals were trained to record in a diary their sleeping and waking hours, meals, intake of medications, and any symptoms or events that could influence blood pressure during this period. Measurements were transferred to a computer for analysis. Monitoring was repeated as necessary until ≥ 70% of the measured values obtained during both daytime and nighttime were satisfactory \[[@b20-krcp-36-167]\].

Transthoracic echocardiography
------------------------------

Transthoracic echocardiography was performed at baseline using a Vivid I ultrasound system (General Electric, Frankfurt, Germany) equipped with a multifre-quency transducer and tissue Doppler imaging software, according to the guidelines of the American Society of Echocardiography \[[@b21-krcp-36-167]\]. Data were analyzed and interpreted by one experienced echocardiographer who was blinded to treatment status and imaging sequence. The LV mass was calculated from the LV linear dimensions using the Devereux formula \[[@b21-krcp-36-167],[@b22-krcp-36-167]\] and normalized to body surface area (BSA) \[[@b21-krcp-36-167],[@b23-krcp-36-167]\]. LV hypertrophy was considered to be present when the LV mass exceeded 115 g/ m^2^ for men and 95 g/m^2^ for women \[[@b21-krcp-36-167]\]. The left atrial (LA) volume was measured using a disk sum algorithm similar to that used to measure LV volume \[[@b24-krcp-36-167],[@b25-krcp-36-167]\] and normalized to BSA. Although the LA size depends on sex, variation due to sex is generally recognized when it is normalized to the BSA \[[@b26-krcp-36-167]\]. Furthermore, whereas several methods of normalizing this measurement have been proposed \[[@b27-krcp-36-167],[@b28-krcp-36-167]\], normalizing to BSA produces the most reliable data. Normalizing to BSA compensates for sexual dimorphism in LA size, so only the normalized value is reported. The recommended highest value for LA size is 34 mL/m^2^\[[@b28-krcp-36-167]--[@b31-krcp-36-167]\] .

Study procedures and assessment
-------------------------------

In this study, we assessed 40 CKD patients with hypertension with polymorphic PVCs. Patients underwent a complete medical history and physical examination. We evaluated the effectiveness of β blocker only or β blocker + exercise onset during 12 months of follow-up regarding the changes of the numbers of PVCs and mean HR by 24-hour-Holter. The follow-up was performed quarterly after the interventions. The renal function was also monitored during the follow-up period.

Statistical analysis
--------------------

The results were expressed as the mean and standard deviation of the mean in the case of normal distribution and as the median with interquartile range otherwise. Statistical tests were all two sided. Comparisons between two-paired values were performed by the paired *t*-test in case of a Gaussian distribution or, alternatively, by the Wilcoxon test. Comparisons between more than two-paired values were performed by ANOVA for repeated measures or with Kruskal--Wallis ANOVA as appropriate complemented by a *post-hoc* test. Frequencies were compared with Fisher's exact test. *P*-values \< 0.05 were considered significant. Correlations between two variables were performed by Pearson in the case of a Gaussian distribution or, alternatively, with the Spearman correlation test. All statistical analysis was performed using the program Graphpad Prism v 7.0 (Graphpad software, La Jolla, CA, USA).

Results
=======

Baseline characteristics of patients and effects on the number of polymorphic PVCs
----------------------------------------------------------------------------------

General features of the 40 subjects are listed in [Table 1](#t1-krcp-36-167){ref-type="table"}. We observed in the β blocker group a significant decrease in the number of polymorphic PVCs from baseline 36,515 ± 3,518 to 3, 6, 9 and 12 months of follow-up, 28,314 ± 2,938, 23,709 ± 1,846, 22,564 ± 1,673, and 22,725 ± 1,415, respectively (*P* \< 0.001 to all the comparisons between the mean of each time point vs. baseline). In the β blocker + exercise group a significant decrease in the number of polymorphic PVCs also occurred from baseline 36,091 ± 3,327 to 3, 6, 9 and 12 months of follow-up, 29,252 ± 3,211, 20,948 ± 2,386, 14,238 ± 3,338, and 6,225 ± 2,319, respectively (*P* \< 0.001 to all the comparisons between the mean of each time point vs. baseline) as shown in [Fig. 1](#f1-krcp-36-167){ref-type="fig"}. Comparisons between the two groups at the same time point just showed differences from the sixth month onwards: at the 6th (Δ = −2,761, *P* = 0.045), 9th (Δ = −8,325, *P* \< 0.001) and 12th (Δ = −16,500, *P* \< 0.001) months.

Effects on renal function and mean heart rate
---------------------------------------------

The changes during the 12 months of follow-up vs. baseline and between groups, after the β blocker or β blocker + exercise onset in mean 24-hour HR Holter monitoring, creatinine values, eGFR, and ACR are displayed in [Table 2](#t2-krcp-36-167){ref-type="table"}.

Correlation
-----------

A significant correlation was found between the variation (Δ) number of polymorphic PVCs at the 12th month (r = −0.933, 95% confidence interval = −0.974 to −0.836, *P* \< 0.001) after the onset of physical activity and the total time of exercise performed per week, as shown in [Fig. 2](#f2-krcp-36-167){ref-type="fig"}.

Discussion
==========

We believe that sympathetic hyperactivity is closely related to the appearance of PVCs. Sympathetic overactivity plays a critical role in the development, maintenance, and aggravation of ventricular arrhythmias \[[@b11-krcp-36-167]\]. Indeed, there is growing appreciation for the role of the sympathetic system in this setting. The effect of endurance training on renal sympathetic nerve activity has been measured in healthy humans \[[@b17-krcp-36-167]\], but not in humans with CKD. Thereafter, identifying the ideal patient population should be considered, as most exercise training studies in patients with CKD include only the healthiest of patients, which may limit the generalizability of the findings \[[@b32-krcp-36-167]\]. Optimization of standard training principles, exercise frequency, intensity, time and type may all influence physiological adaptations and thus need to be studied. The duration of previous studies in clinical populations has typically been 4 months of training at a moderate intensity, 3 days/week while studies in healthy populations have been considerably shorter in duration \[[@b13-krcp-36-167]\]. Longer duration interventions (≥ 4 months) are more effective in lowering sympathetic activity in other clinical populations, thus Professor Esler's group recommend adopting a similar approach in patients with CKD \[[@b12-krcp-36-167]\], because it was previously proved in healthy individuals that intense endurance training has a more pronounced effect on autonomic balance \[[@b33-krcp-36-167]\], which may be beneficial to patients with high sympathetic tone.

Our findings showed that after the physical activity onset, the number of PVCs and the mean 24-hour HR Holter monitoring decreased during the follow-up period in comparison to baseline and vs. sedentary group. As well, the creatinine values and the ACR reduced. Consequently, the eGFR increased. A significant correlation was found between the Δ number of polymorphic PVCs at the 12th month after the onset of physical activity and the total time of exercise performed per week. In conclusion, our data suggest that the long-term exercise can reduce ventricular arrhythmias and improve the renal function.

This study has some limitations. The non-use of cardiac magnetic resonance occurred because the use of gadolinium, which could lead to nephrogenic systemic fibrosis in chronic kidney disease population \[[@b34-krcp-36-167]\]. We chose patients with structurally normal heart, to make sure there were no other mechanisms involved in the genesis and maintenance of polymorphic PVCs, beyond the hypothetical mechanisms, aforementioned.

Whilst there was an improvement in the number of polymorphic PVCs, and renal function in the β blocker + exercise group in comparison to β blocker group, these findings should be interpreted with caution given the unblinded non-randomised nature of the study. A randomised trial with appropriate concealment of treatment, more patients and for a long follow-up period is required to address the potential benefits of physical activity in polymorphic PVCs.

In conclusion, polymorphic PVCs may be modifiable by physical activity in CKD patients with hypertension without structural heart disease according to the aforementioned results. Although encouraging, our data are preliminary and need to be validated in a large population and in the long term.
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###### 

General features of patients at baseline

  Parameter                                β blocker (n = 20)   β blocker + exercise (n = 20)   *P*
  ---------------------------------------- -------------------- ------------------------------- ------
  Age (yr)                                 58 ± 12              62 ± 10                         0.24
  Body mass index (kg/m^2^)                26.4 ± 2.6           25.4 ± 2.1                      0.19
  Male gender                              12 (60.0)            15 (75.0)                       0.50
  White ethnicity                          17 (85.0)            14 (70.0)                       0.45
  Polymorphic PVCs                         34,515 ± 3,518       36,091 ± 3,327                  0.70
  Type 2 Diabetes mellitus                 10 (50.0)            8 (40.0)                        0.75
  Antihypertensive                                                                              
   ACE-inhibitors/ARB                      20 (100)             20 (100)                        1.00
   Diuretics                               20 (100)             20 (100)                        1.00
   DHP Ca^++^ channel blockers             20 (100)             20 (100)                        1.00
   Clonidine                               12 (60.0)            10 (50.0)                       0.75
  Echocardiographic parameters                                                                  
   Indexed left atrial volume (mL/m^2^)    29.8 ± 3.0           31.5 ± 4.2                      0.15
   Interventricular septum tickness (mm)   10.6 ± 0.7           11.0 ± 0.9                      0.13
   LVPWT (mm)                              9.1 ± 1.0            9.4 ± 0.7                       0.28
   LVEF, Simpson (%)                       65.4 ± 10.0          66.5 ± 12.2                     0.76
   LVEDD (mm)                              45.4 ± 3.5           43.8 ± 5.1                      0.25
   LVESD (mm)                              31.7 ± 5.2           32.0 ± 6.3                      0.87
   LV mass index (g/m^2^)                  88.5 ± 13.2          97.4 ± 17.5                     0.08

Values are expressed as mean ± standard deviation or number (%).

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; DHP, dihydropyridine; LV, left ventricular; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVPWT, left ventricular posterior wall thickness; PVCs, premature ventricular complexes.

###### 

Mean 24-hour heart rate Holter monitoring, ABPM and renal function at baseline and during follow-up

  Parameter                                 β blocker (n = 20)   β blocker + exercise (n = 20)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  ----------------------------------------- -------------------- ---------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- ----------------------------------------------------------- ------------- ---------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------
  Mean 24-hour ABPM (mmHg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
   Systolic                                 126 ± 2.4            118 ± 2.5[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}    119 ± 2.6[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}    117 ± 2.3[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}    116 ± 2.6[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}     125 ± 2.9     117 ± 3.2[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}                                              116 ± 3.5[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}[†](#tfn7-krcp-36-167){ref-type="table-fn"}   115 ± 3.1[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}[†](#tfn7-krcp-36-167){ref-type="table-fn"}     112 ± 2.6[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}[†](#tfn7-krcp-36-167){ref-type="table-fn"}
   Diastolic                                76 ± 2.9             71 ± 2.0[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}     68 ± 1.9[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}     66 ± 1.8[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}     64 ± 1.8[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}      75 ± 2.7      65 ± 2.4[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}[††](#tfn8-krcp-36-167){ref-type="table-fn"}   62 ± 1.3[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}[††](#tfn8-krcp-36-167){ref-type="table-fn"}   61 ± 1.0[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}[††](#tfn8-krcp-36-167){ref-type="table-fn"}     61 ± 0.8[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}[††](#tfn8-krcp-36-167){ref-type="table-fn"}
  Mean 24-hour HR Holter monitoring (bpm)   81.5 ± 5.1           70.3 ± 3.9[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}   69.5 ± 3.1[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}   67.1 ± 3.8[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}   64.8 ± 2.6[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}    81.2 ± 4.6    72.9 ± 3.1[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}                                             67.5 ± 3.2[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}                                             58.3 ± 3.5[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}[††](#tfn8-krcp-36-167){ref-type="table-fn"}   55.7 ± 3.3[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}[††](#tfn8-krcp-36-167){ref-type="table-fn"}
  Creatinine (mg/dL)                        1.88 ± 0.33          --                                                         1.95 ± 0.3[\*](#tfn5-krcp-36-167){ref-type="table-fn"}     --                                                         2.06 ± 0.29[\*](#tfn5-krcp-36-167){ref-type="table-fn"}     1.91 ± 0.32   --                                                                                                   1.73 ± 0.30[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}                                            --                                                                                                     1.60 ± 0.29[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}[†](#tfn7-krcp-36-167){ref-type="table-fn"}
  eGFR (mL/min/1.73 m^2^)                   36.3 ± 10.3          --                                                         34.4 ± 8.2                                                 --                                                         31.8 ± 6.8[\*](#tfn5-krcp-36-167){ref-type="table-fn"}      35.9 ± 9.8    --                                                                                                   41.0 ± 12.7[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}                                            --                                                                                                     44.8 ± 13.3[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}[†](#tfn7-krcp-36-167){ref-type="table-fn"}
  ACR (mg/g)                                80.6 ± 21.7          --                                                         85.6 ± 22.8[\*](#tfn5-krcp-36-167){ref-type="table-fn"}    --                                                         94.9 ± 20.8[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}   83.1 ± 22.9   --                                                                                                   74.3 ± 21.4[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}                                            --                                                                                                     65.1 ± 19.3[\*\*](#tfn6-krcp-36-167){ref-type="table-fn"}[†](#tfn7-krcp-36-167){ref-type="table-fn"}

Values presented as mean ± standard deviation.

ABPM, ambulatory blood pressure measurements; ACR, albumin:creatinine ratio; eGFR, estimated glomerular filtration rate; HR, heart rate.

*P* \< 0.05 and

*P* \< 0.001 vs. baseline values,

*P* \< 0.05 and

*P* \< 0.001 to the comparison of the means between groups in the same time point.
